Alembic Pharma shares slide 4% on Q3 profit miss; is it a good time to buy? (Soban News)

Analysts at Motilal Oswal Financial Services (MOFSL) have retained their Neutral rating on Alembic Pharma, with a target price of ₹860 per share​Analysts at Motilal Oswal Financial Services (MOFSL) have retained their Neutral rating on Alembic Pharma, with a target price of ₹860 per share ​Latest News [ SOBAN NEWS: International and National ]